DGS warns that overcrowding, patient vulnerability and failure to control infections may contribute to the spread of resistant bacteria, the prevention of which requires more than reducing antibiotic consumption.
© Lusa
18/11/2026
by
Lusa
Soblation, vulnerability of patients and failure to control infections in health services can contribute to the spread of resistant bacteria, whose prevention requires more than reducing the consumption of antibiotics, today warned the Directorate-General for Health.
“ The national reality shows that the decrease in global antibiotic consumption can coexist with the increase in certain resistances. Therefore, the goal is not only to prescribe less, but to prescribe better”, says DGS in a response to the Lusa agency on European Antibiotic Day, highlighted today
The health authority points out that it is necessary to “use the appropriate antibiotic, when there is clinical indication, at the correct dose and during the recommended period”.
According to DGS, Portugal has made progress in reducing the consumption of antibiotics and controlling some resistance, but faces challenges in relation to bacteria resistant to these medicines.
Of the three indicators of bacterial resistance with national targets defined within the European Union for 2030, Portugal has already achieved the goal for methicillin-resistant ‘Staphylococcus aureus’ (MRSA).
Between 2019 and 2025, the estimated incidence of bloodstream infections by this bacterium decreased by 31.3%, exceeding the 18% reduction target.
On the contrary, the incidence of ‘Escherichia coli’ blood stream infections resistant to third-generation cephalosporins increased 31.9% when the established target is a 12% reduction.
The DGS considers the evolution of carbapenem-resistant ‘Klebsiella pneumoniae’, whose incidence has more than doubled from 2.93 to 6.06 cases per 100,000 inhabitants, to be “particularly worrying”.
This move takes Portugal away from the 5% reduction target by 2030 and is a priority of the Antimicrobial Prevention and Control Programme (PPCIRA).
Carbapenemes are last-line antibiotics, fundamental in the treatment of certain serious infections, so resistance to these medicines significantly limits therapeutic options, says DGS, noting that this scenario is shared by many European countries.
Regarding the consumption of antibiotics, it indicates that between 2019 and 2025, Portugal had a reduction of 5.2%, approaching the reduction target of 9% by 2030.
The proportion of antibiotics in the first or second line drug group for many frequent infections increased from 61.4% to 61.9%, remaining below the target of at least 65%.
DGS states that antibiotic resistance is associated with the use of these drugs and the transmission of resistant bacteria, explaining that whenever an antibiotic is used, sensitive bacteria are eliminated or inhibited, while resistant bacteria are more likely to survive and multiply.
“ The unnecessary or inadequate use, in particular of wider spectrum antibiotics than necessary, favors this process”, he warns.
However, it also warns, the reduction in consumption is not enough: “Prevention of the transmission of resistant bacteria, particularly in health services, is also essential. Overcrowding, vulnerability of patients and failures in the application of infection prevention and control measures can contribute to their spread,” he warns.
It maintains that antibiotic resistance may make infections such as urinary infections, pneumonias or wound infections more difficult to treat, increasing the risk of complications and mortality and may require the use of less effective or more toxic medicines.
DGS also stresses that antibiotic efficacy is also essential for the safety of complex medical procedures such as surgeries, transplants, cancer treatments and intensive care. Preserving these medicines is therefore a fundamental condition for the quality and safety of health care.




